INTRODUCTION AND OBJECTIVES: Monopolar transurethral resection of the prostate (TURP) is the treatment of choice and most frequently performed surgery for prostate glands over 80 cc. Thulium fiber laser enucleation of the prostate (ThuFLEP) is a less invasive treatment option for BPH due to minimal penetration of laser energy (0.2 mm) and tissue coagulation. The aim of our study was to compare the efficacy of TURP and ThuFLEP in management of BPH in patients with small prostate glands (<80 cc).
METHODS: This retrospective study included 398 patients with prostate volume less than 80 cc aged 66.1 (54-82) years with infravesical obstruction (IPSS>20, Qmax<12) due to BPH. Group A (140 patients) underwent ThuFLEP (mean prostate volume, 65.9 cc) and group B (258 patients) underwent TURP (mean prostate volume, 63.3 cc). Patients with urethral strictures, bladder stones or a history of prior prostate surgery were excluded. For enucleation, we used Urolase (NTO IRE-POLUS, Russia), a 120 W thulium fiber laser, and a 600 µm fiber. Tissue removal from the bladder was performed with a Piranha morcellator (Richard Wolf, Germany). Prior to and following surgery, serum sodium and hemoglobin levels were assessed. Preoperatively and six months after surgery we evaluated IPSS, QoL, Qmax and post-void residual volume. A p-value of 0.05 was chosen as a threshold for statistical significance.
RESULTS: Mean surgery time in the ThuFLEP group was higher (48.1AE17.6 min) than in the TURP group (37.9AE18.6 min) (p<0.001). Mean mass of removed tissue was 54.0 g in group D and 49.4 g in group B. Catheterization time was 1.4 days in group A and 2.4 days in group B. Hospital stay was 3.4 days in group A and 4.7 days in group B. Stress urinary incontinence following catheter removal was observed in 7.9% of cases in group A and in 14.4% of cases in group B (p[0.256). Hemoglobin level decreased by an average of 1.01 g/dL in group A and 1.8 g/dL in group B (p<0.001). Similarly, serum sodium level decreased by an average of 1.1 mmol/L in group A and 4.1 mmol/L in group B (p<0.001). Postoperative bleeding necessitating blood transfusion and TURP-syndrome were noted in 1 patient (0.4%) after TURP. Six months after surgery, we observed statistically significant improvement in IPSS, QoL, Qmax and post-void residual volume in all the patients (p<0.001). There were no differences in the above mentioned parameters between the two groups.
CONCLUSIONS: Despite taking longer to perform, ThuFLEP for BPH in patients with small prostate glands (>80 cc) offered improvement in voiding parameters e comparable to those after TURP e while at the same time showing decreased postoperative complication rates.
Source of Funding: none

V02-06 TRANSURETHRAL THULIUM LASER PROSTATECTOMY IN THE OUTPATIENT SETTING: TECHNIQUE AND OUTCOMES AT A SINGLE CENTER IN THE UNITED STATES
Richard Grunert*, David Sobel, Curran Uppaluri, Theodore Cisu, Colchester, VT INTRODUCTION AND OBJECTIVES: Thulium laser prostatectomy is a versatile laser that allows for vaporization, vaporesection ,vaponucleation and enucleation and morcellation of benign prostatic hyperplasia (BPH). In an effort to seek out procedures to avoid inpatient hospitalization while maintaining superior hemostasis, this study details the ongoing experience utilizing thulium laser vaporization in the outpatient setting.
METHODS: A retrospective chart review of patients who underwent thulium laser vaponucleation between 2014 and 2018 was performed. AUA symptom scores, PSA reduction, duration of catheterization, and postoperative complications were analyzed. All procedures were performed by a single surgeon at a single institution utilizing 150 watt and later a 200 watt laser for surgery.
Representative videos we taken from live surgery to create a surgical techniques video.
RESULTS: 128 patients were included in the analysis. 11 patients were anti-coagulated and 11 patients had concurrent cystolithalopaxies performed. 25 patients had repeat procedures from prior TURPs or green light laser prostatectomies. Of the primary cases, the mean prostate size was 56 gm (range 15-167gm). 121 (95%) patients were able to be discharged as outpatients the day of surgery. The mean preoperative AUA symptom scores, generally on maximal medical therapy, were 19.1 and 16.8 for primary and repeat, respectively. The mean AUA symptom scores were significantly reduced to 6.1 and 8.2 (p < 0.005 for both), respectively, at 3-month follow-up (128 pts) and further reduced to 5.1 and 6.0 (p < 0. 005 for both), respectively, at 12-month follow-up (71 pts) and 6.0 (p < 0.0001) at 24 months (37 pts). For primary patients, the mean preoperative PSA was 4.1 ng/mL (range 0.2-37.0) and the postoperative PSA was 1.5 ng/mL (63.4% reduction; range 0.1-10.3). Ejaculatory function was unchanged in 65 patients (57.8%) and worsening erectile function occurred with 12 patients (10.2%). Transient short-term stress incontinence occurred in 5 patients and resolved in all but one that required a sling procedure. 3 patients required a repeat resection and 1 patient had a bladder neck contracture. 57 patients (46.2%) required two or fewer days of postop catheterization, with a mean of 2.8 days (range 0-14 days). 5/117 of patients overall (4.3%) went into clot retention 2 requiring delayed admission and continuous bladder irrigation.
CONCLUSIONS: Our experience suggests that thulium laser vaporization of the prostate is a safe, effective and durable alternative for the treatment of BPH with results comparable to published traditional inpatient electrosurgical methods. Our analysis suggest that effective laser therapy offers an advantage by greatly reducing the need for hospitalization without compromising efficacy of traditional electrosurgical methods. METHODS: In a prospective and random model, 20 men who underwent to BPH surgical treatment were allocated in two groups (RASP and TST-RASP). Demographic and preoperative data (including IPSS and Flowmetry scores) were collected.
The procedures were carried-out using the Si da Vinci Robotic System (Intuitive Surgical). Through a five-trocars transperitoneal access, we perform a longitudinal incision of the bladder wall and prostate capsule and the removal of prostatic adenoma in both groups. Next, using a three-steps reconstructive technique, a 360 trigonization of the bladder mucosa was proposed in TST-RASP group (Tunnel-Shaped Trigonization) rather than classic trigonization (RASP group). The TST enrolls the advancement of a bladder mucosa flap until the prostatic urethra (first step) followed by a running suture between the advanced mucosa and prostatic capsule bilaterally (second step). At this point the prostate capsule should be totally isolated from the rest of the urinary tract. Finally, a tunnel conformation is achieved closing both sides of the Vol. 201, No. 4S, Supplement, Friday, May 3, 2019 THE JOURNAL OF UROLOGY Ò e165
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